Online citations, reference lists, and bibliographies.
← Back to Search

Poly (d, L-lactide-co-glycolide) Nanoparticles For Sustained Release Of Tacrolimus In Rabbit Eyes.

M. A. Kalam, A. Alshamsan
Published 2017 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
Tacrolimus (TAC)-loaded Ploy-lactide-co-glycolide nanoparticles (PLGA-NPs) was developed by emulsification-diffusion method for topical ocular delivery in certain ocular conditions where therapeutic level of immunomodulator into eyes is required for sufficient duration. So, we optimized TAC-loaded PLGA-NPs with higher TAC payload. The mean particle-size and its distribution, polydispersity, zeta-potentials, morphology, drug encapsulation and loading capacity of NPs were analyzed. Transcorneal permeation through excised rabbit cornea revealed instant and controlled permeation of TAC from TAC-aqueous suspension (TAC-AqS) and from PLGA-NPs, respectively. Stability study results indicated that there were no significant changes in above characteristics for 1-month storage at 25°C. The safety of PLAG was established by modified Draize's test after its topical administration in rabbit eyes. The adopted liquid chromatography-electrospray ionization tandem mass spectrometry was successfully applied for TAC quantification in ocular tissues and aqueous-humor. PLGA-NPs improved corneal, conjunctival and aqueous humor bioavailability of TAC. A considerably higher TAC-concentration from F2 was found in ocular tissues even at 24h and in aqueous humor till 24h following its topical ocular administration as compared to TAC-AqS. The PLGA-NPs significantly enhanced ocular bioavailability of TAC than that of aqueous suspension.
This paper references
10.1038/eye.2011.75
Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis
A. Kheirkhah (2011)
Influence of the degrees of hydrolyzation and polymerization of poly (vinylalcohol) on the preparation and properties of poly(dl-lactide-coglycolide) nanoparticle
H. Murakami (1997)
10.1016/0169-409X(95)00017-2
Microspheres and nanoparticles used in ocular delivery systems
A. Zimmer (1995)
10.1111/j.1755-3768.2008.01347.x
Vernal keratoconjunctivitis: a major review
S. Kumar (2009)
10.1016/j.geb.2003.09.006
Preparation
M. Voorneveld (2004)
10.3791/51015
PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS
Rebecca L. McCall (2013)
10.1016/j.jsps.2016.06.009
Development and characterization of methoxy poly(ethylene oxide)-block-poly(ε-caprolactone) (PEO-b-PCL) micelles as vehicles for the solubilization and delivery of tacrolimus
R. Ali (2017)
10.2147/IJN.S71198
Conjugation of cell-penetrating peptides with poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug delivery
Aimee Vasconcelos (2015)
Preparation characterization , and evaluation of gati fl oxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system
J. Carlfors Edsman (2010)
10.1016/J.BIOMATERIALS.2006.11.028
Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP).
Y. Diebold (2007)
10.1097/ICO.0b013e31823f8c9b
Clinical Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops
B. Moscovici (2012)
10.1016/j.colsurfb.2016.08.048
Improving the topical ocular pharmacokinetics of an immunosuppressant agent with mucoadhesive nanoemulsions: Formulation development, in-vitro and in-vivo studies.
S. Akhter (2016)
10.3390/ijms151223909
PLGA Biodegradable Nanoparticles Containing Perphenazine or Chlorpromazine Hydrochloride: Effect of Formulation and Release
Mohammed Halayqa (2014)
10.1080/21691401.2016.1203794
PLGA nanoparticles for ocular delivery of loteprednol etabonate: a corneal penetration study
A. K. Sah (2017)
Immunosuppressive agents: Role in corneal graft rejection
R. Sinha (2013)
10.4103/2230-973X.106981
Formulation strategies for drug delivery of tacrolimus: An overview
P. Patel (2012)
10.2147/IJN.S3938
Preparation, characterization and in-vitro evaluation of sustained release protein-loaded nanoparticles based on biodegradable polymers
B. Mukherjee (2008)
10.1089/jop.2007.0086
Absorption, distribution, and excretion of 14C-labeled tacrolimus (FK506) after a single or repeated ocular instillation in rabbits.
E. Fujita (2008)
Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye.
U. Pleyer (1993)
10.1089/jop.2011.0108
Ocular safety and pharmacokinetics study of FK506 suspension eye drops after corneal transplantation.
J. Yuan (2012)
10.1002/jbm.a.34040
Effects of surfactants on the properties of PLGA nanoparticles.
Jyothi U Menon (2012)
10.1016/J.IJPHARM.2003.07.010
Establishment of new preparation method for solid dispersion formulation of tacrolimus.
K. Yamashita (2003)
A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children.
P. Labcharoenwongs (2012)
10.1016/J.OPHTHA.2007.07.025
Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases.
D. Miyazaki (2008)
10.1016/S0928-0987(97)00075-4
Rheological evaluation of poloxamer as an in situ gel for ophthalmic use.
K. Edsman (1998)
10.14573/altex.1510053
Analysis of Draize Eye Irritation Testing and its Prediction by Mining Publicly Available 2008–2014 REACH Data
T. Luechtefeld (2016)
10.1515/9783111576855-009
D
Saskia Bonjour (1824)
10.1016/b978-0-12-384931-1.00016-7
P
J. Lackie (2013)
10.1016/S0939-6411(00)00087-4
Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art.
R. Mueller (2000)
10.1111/j.1444-0938.2010.00553.x
Drug delivery to the posterior segment of the eye through hydrogel contact lenses
C. Schultz (2011)
10.1016/j.ijpharm.2009.06.020
Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery.
N. Li (2009)
10.1089/jop.2009.0087
A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis.
Y. Ohashi (2010)
10.1016/j.cmpb.2010.01.007
PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel
Y. Zhang (2010)
10.1007/s10384-004-0187-3
Comparison of Topical Dexamethasone and Topical FK506 Treatment for the Experimental Allergic Conjunctivitis Model in Balb/c Mice
J. Shoji (2004)
10.1097/01.ico.0000151507.49565.6e
Topical Tacrolimus Ointment for Treatment of Refractory Anterior Segment Inflammatory Disorders
M. A. Joseph (2005)
10.1023/B:PHAM.0000022411.47059.76
The Characteristics and Mechanisms of Uptake of PLGA Nanoparticles in Rabbit Conjunctival Epithelial Cell Layers
Mohamed G. Qaddoumi (2004)
10.1016/S0378-5173(99)00187-8
Preparation of poly(DL-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method.
H. Murakami (1999)
10.1080/02713680802149115
Topical Tacrolimus 0.03% Ointment for Intractable Allergic Conjunctivitis: An Open-Label Pilot Study
Liat Attas-Fox (2008)
10.1111/j.1600-0404.1981.tb07743.x
ABSORPTION
(1981)
10.1001/ARCHDERM.135.5.574
Tacrolimus: the drug for the turn of the millennium?
T. Ruzicka (1999)
10.1002/JPS.2600640811
Ocular evaluation of polyvinyl alcohol vehicle in rabbits.
T. Patton (1975)
10.1016/S0927-7757(00)00825-6
Preparation of PLGA nanoparticles containing estrogen by emulsification–diffusion method
Hye young Kwon (2001)
10.3109/10611860903338462
Preparation, characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system
M. A. Kalam (2010)
10.2165/11587010-000000000-00000
Tacrolimus in the Treatment of Ocular Diseases
Jiajie Zhai (2012)
10.1081/DDC-100102197
Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method.
J. Barichello (1999)
10.1016/j.ijbiomac.2016.05.016
The potential application of hyaluronic acid coated chitosan nanoparticles in ocular delivery of dexamethasone.
M. A. Kalam (2016)
10.1089/jop.2007.0083
Pharmacokinetics and tissue distribution of tacrolimus (FK506) after a single or repeated ocular instillation in rabbits.
E. Fujita (2008)
10.1016/j.colsurfb.2014.09.042
Physicochemical characterization of epigallocatechin gallate lipid nanoparticles (EGCG-LNs) for ocular instillation.
J. Fangueiro (2014)
10.1111/jphp.12132
Topical delivery of ocular therapeutics: carrier systems and physical methods
J. G. Souza (2014)
10.1159/000099252
Anatomy and immunology of the ocular surface.
E. Knop (2007)
Development of a UPLC-MS/MS method for determination of tacrolimus and cyclosporine a in human whole blood
S. Wang (2015)
10.1515/9783111548050-024
M
M. Sankar (1824)
10.1089/jop.2007.0059
Preliminary study of the effect of FK506 nanospheric-suspension eye drops on rejection of penetrating keratoplasty.
Wen-lei Fei (2008)
METHODS FOR THE STUDY OF IRRITATION AND TOXICITY OF SUBSTANCES APPLIED TOPICALLY TO THE SKIN AND MUCOUS MEMBRANES
J. H. Draize (1944)
10.1007/s13318-013-0149-6
Pharmacokinetic interaction studies of fenugreek with CYP3A substrates cyclosporine and carbamazepine
F. Al-Jenoobi (2013)
10.1016/j.ejpb.2009.08.006
Preparation and evaluation of tacrolimus-loaded nanoparticles for lymphatic delivery.
Sae-Byeok Shin (2010)
10.1016/j.nano.2009.10.004
Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery.
H. Gupta (2010)
10.1016/j.ijbiomac.2016.04.070
Development of chitosan nanoparticles coated with hyaluronic acid for topical ocular delivery of dexamethasone.
M. A. Kalam (2016)
A Randomized ,
M. Hilbink (2009)
10.1016/S0378-5173(96)04854-5
Influence of the Degrees of Hydrolyzation and Polymerization of Poly(vinylalchol)on the Preparation and Properties of Poly(DL-lactide-co-glycolide)nanoparticle.
Murakami (1997)
10.1016/j.ajo.2012.12.009
Application for tacrolimus ointment in treating refractory inflammatory ocular surface diseases.
Young Ji Lee (2013)
10.1016/j.jchromb.2008.04.028
Determination of tacrolimus in rabbit aqueous humor by liquid chromatography-electrospray ionization tandem mass spectrometry.
J. Yuan (2008)
Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders.
A. C. Cheng (2006)
10.1016/J.JCONREL.2004.07.001
Model of transient drug diffusion across cornea.
W. Zhang (2004)
10.1016/j.ajps.2016.08.006
The studies of PLGA nanoparticles loading atorvastatin calcium for oral administration in vitro and in vivo
Zhenbao Li (2017)
10.1515/9783111576855-015
J
Seguin Hen (1824)



This paper is referenced by
10.1016/j.ajps.2018.08.001
Extended tacrolimus release via the combination of lipid-based solid dispersion and HPMC hydrogel matrix tablets
Hui Xu (2019)
10.1016/j.ijpharm.2019.118573
Treatment of Endotoxin-Induced Uveitis by Topical Application of Cyclosporine A-Loaded PolyGelTM in Rabbit Eyes.
A. Alshamsan (2019)
10.1016/j.ijbiomac.2018.04.122
Chitosan coated PLGA nanoparticles amplify the ocular hypotensive effect of forskolin: Statistical design, characterization and in vivo studies.
N. Khan (2018)
10.1016/j.ijpharm.2018.05.050
Development of fluorometholone‐loaded PLGA nanoparticles for treatment of inflammatory disorders of anterior and posterior segments of the eye
Roberto González-Pizarro (2018)
10.1016/j.mimet.2019.01.020
Antifungal efficacy of Itraconazole loaded PLGA-nanoparticles stabilized by vitamin-E TPGS: In vitro and ex vivo studies.
A. Alhowyan (2019)
10.1097/MOT.0000000000000564
Novel targeted drug delivery systems to minimize systemic immunosuppression in vascularized composite allotransplantation
Adriano Taddeo (2018)
10.1038/s41598-020-63767-1
Mitigation of Tacrolimus-Associated Nephrotoxicity by PLGA Nanoparticulate Delivery Following Multiple Dosing to Mice while Maintaining its Immunosuppressive Activity
Aws Alshamsan (2020)
10.2147/IJN.S247443
Targeted Prodrug-Based Self-Assembled Nanoparticles for Cancer Therapy
Weiwei Wang (2020)
10.1007/s13205-020-2077-x
Anti-tumor effect of PEG-coated PLGA nanoparticles of febuxostat on A549 non-small cell lung cancer cells
M. Alfaifi (2020)
10.1167/iovs.17-22829
Sustained Connexin43 Mimetic Peptide Release From Loaded Nanoparticles Reduces Retinal and Choroidal Photodamage.
N. M. Mat Nor (2018)
10.1016/j.jsps.2020.07.001
Thermoresponsive sol-gel improves ocular bioavailability of Dipivefrin hydrochloride and potentially reduces the elevated intraocular pressure in vivo
Musaed Alkholief (2020)
10.1016/j.yrtph.2020.104757
Advances in selecting appropriate non-rodent species for regulatory toxicology research: Policy, ethical, and experimental considerations.
Yong-Wook Son (2020)
10.22270/jddt.v10i1-s.3853
Formulation and Characterization of Moxifloxacin Nanoparticles with Ion Exchange Resin
Jigar Vyas (2020)
10.1080/21691401.2019.1683567
Characterisation of 2-HP-β-cyclodextrin-PLGA nanoparticle complexes for potential use as ocular drug delivery vehicles
Fan Li (2019)
10.1080/10717544.2019.1582728
Development and effects of tacrolimus-loaded nanoparticles on the inhibition of corneal allograft rejection
Q. Wu (2019)
10.1016/j.jddst.2020.101912
Positively charged polymeric nanoparticles improve ocular penetration of tacrolimus after topical administration
B. F. Castro (2020)
10.1016/j.addr.2018.06.023
Unintended effects of drug carriers: Big issues of small particles
H. Parhiz (2018)
10.1002/adtp.201900157
Composite Thermoresponsive Hydrogel with Auranofin‐Loaded Nanoparticles for Topical Treatment of Vaginal Trichomonad Infection
Y. Zhang (2019)
10.1016/j.drudis.2019.02.001
Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties.
Astrid Subrizi (2019)
Semantic Scholar Logo Some data provided by SemanticScholar